US Pharm. 2010;35:50.
Teva Pharmaceutical Industries Ltd. announced that the U.S. Court of Appeals for the District of Columbia Circuit ruled in its favor by overturning a July 2009 district court decision, which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar (hydrochlorothiazide; losartan potassium) and Cozaar (losartan potassium). Teva's ANDAs will be eligible for final approval this month, when the method of use patent expires. Teva should be eligible to receive 180-day Hatch-Waxman statutory exclusivity to market these products.
